Loomis biotech volatility around trial results
The Flowmaster highlighted the extreme volatility in Loomis (ALMS) around clinical trial results, with a recent 50% drop followed by call buying despite downgrades.
Keep reading this one
You've read the thesis and who argued it. A free account opens the argument, what validates it, the risks the show raised, and the moment in the episode where it was said — 3 ideas in full a day, no card.